Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Humanized antibody Stories

2014-04-16 09:48:04

Over 20 years after the fatal fialuridine trial, a study published this week in PLOS Medicine demonstrates that mice with humanized livers recapitulate the drug's toxicity. The work suggests that this mouse model should be added to the repertoire of tools used in preclinical screening of drugs for liver toxicity before they are given to human participants in clinical trials. A retrospective analysis by the US National Academy of Sciences of all preclinical fialuridine toxicity tests, which...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-01-06 10:17:40

Earlier amyloid-beta assemblies may be one of the most important causes of Alzheimer's disease. Passive immunization of anti-amyloid-beta antibodies can reduce amyloid-beta burden and improved memory performance in various Alzheimer's disease animal models or patients. Screening humanized antibodies from a human Fab phage display library is an effective and quick method to obtain beta-amyloid oligomers. Thus, a recent study published in the Neural Regeneration Research (Vol. 8, No. 33, 2013)...

2013-11-21 23:28:43

Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement. Somerset, NJ, and Austin, TX (PRWEB) November 21, 2013 Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug...

2013-09-26 20:21:49

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates. Monoclonal antibodies are the most successful biologic therapeutics on the market. More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of...

2013-08-07 16:28:09

TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Patent and Trademark Office granted U.S. Patent No. 8,502,018 relating to methods of genetically modifying a mouse to make human antibodies. A similar European patent, EP 1 360 287 B1, was granted by the European Patent Office on September 12, 2012. These patents form part of Regeneron's global patent portfolio, which together protect fundamental...

2013-04-16 12:26:37

DUBLIN, Ireland, April 16, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013 [http://www.researchandmarkets.com/research/7rg77r/antibody ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of 504...

2013-03-26 11:03:41

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels...

2013-02-01 08:25:50

DALLAS, Feb. 1, 2013 /PRNewswire-iReach/ -- It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (Abbvie) and Trastuzumab (Roche) reached above USD5 billion around the globe, approximating 60% of global...